The Cell Cycle Explained: From Growth to Division

Overview of the Phases

The cell cycle is divided into two major periods: interphase, during which the cell grows and replicates its DNA, and the mitotic (M) phase, during which the cell divides. Interphase is further subdivided into three phases: G1 (first gap), S (synthesis), and G2 (second gap). In a typical mammalian cell dividing every 24 hours, G1 lasts approximately 11 hours, S phase about 8 hours, G2 about 4 hours, and M phase roughly 1 hour. The gap phases are not idle periods of waiting but rather active times during which the cell grows, synthesizes proteins, produces organelles, and prepares for the demands of DNA replication and division.

Many cells in the adult body are not actively dividing. These cells exit the cell cycle from G1 and enter a quiescent state called G0. Some cells, such as mature neurons and cardiac muscle cells, remain in G0 permanently and never divide again under normal circumstances. Other cells, such as liver cells (hepatocytes), remain in G0 but can re-enter the cell cycle in response to specific signals, such as those produced after liver injury or partial hepatectomy. Stem cells and the rapidly dividing cells of the bone marrow, intestinal lining, and skin continuously cycle through the cell cycle to replace cells that are lost through normal wear and apoptosis.

G1 Phase: Growth and Preparation

During G1, the cell grows in size, synthesizes proteins, and produces additional organelles in preparation for DNA replication. This is the phase during which the cell integrates signals from its environment to decide whether to proceed with division. Growth factors, nutrients, and cell-cell contacts all influence this decision. If conditions are favorable, the cell passes a critical decision point late in G1 called the restriction point (in mammalian cells) or Start (in yeast). After passing the restriction point, the cell is committed to DNA replication and division and no longer requires external growth factor signals to complete the cycle.

The molecular machinery that drives passage through the restriction point involves the retinoblastoma protein (Rb), a tumor suppressor that normally inhibits the E2F family of transcription factors. In early G1, Rb is in its active, hypophosphorylated form and blocks E2F from activating the genes needed for S phase entry. Growth factor signaling stimulates the production of cyclin D, which binds and activates CDK4 and CDK6. These cyclin-CDK complexes begin phosphorylating Rb, partially inactivating it. This allows some E2F activity, which promotes the expression of cyclin E. Cyclin E activates CDK2, which further phosphorylates Rb in a positive feedback loop that fully inactivates Rb and unleashes the complete E2F transcriptional program needed for S phase entry.

S Phase: DNA Replication

During S phase, the cell replicates its entire genome, producing two identical copies of each chromosome. In human cells, this means duplicating approximately 6.4 billion base pairs of DNA distributed across 46 chromosomes. Replication begins simultaneously at thousands of replication origins along each chromosome, with each origin firing once and only once per cell cycle. This single-firing rule is enforced by a licensing system in which pre-replication complexes are loaded onto origins during G1 but can only be activated by S phase kinases, after which the licensing factors are degraded or exported from the nucleus to prevent re-replication.

Each replicated chromosome now consists of two identical sister chromatids joined at the centromere by cohesin protein complexes. The sister chromatids will remain attached throughout G2 and into mitosis, when they will be separated and distributed to the two daughter cells. DNA replication is remarkably accurate, with the replicative polymerases making roughly one error per billion nucleotides copied thanks to their built-in proofreading activity. Mismatch repair enzymes correct most of the remaining errors after replication, reducing the final error rate to approximately one mutation per cell division.

G2 Phase: Final Preparation for Division

During G2, the cell continues to grow and synthesizes the proteins needed for mitosis, including tubulin for the mitotic spindle and components of the chromosome condensation machinery. The cell also conducts a final check of its replicated DNA, activating repair mechanisms to fix any damage that occurred during replication or from environmental insults such as radiation or chemical mutagens. The G2/M checkpoint ensures that cells with incompletely replicated or damaged DNA do not enter mitosis, where the consequences of attempting to segregate damaged chromosomes could be catastrophic.

The transition from G2 to M phase is driven by the activation of the cyclin B-CDK1 complex, historically known as maturation promoting factor (MPF). Cyclin B accumulates throughout S and G2 but is kept inactive by inhibitory phosphorylation of CDK1 by the kinases Wee1 and Myt1. At the G2/M transition, the phosphatase Cdc25 removes these inhibitory phosphates, rapidly activating cyclin B-CDK1 in an explosive positive feedback loop (active CDK1 activates more Cdc25 while inhibiting Wee1). This switch-like activation ensures a sharp, decisive entry into mitosis rather than a gradual transition.

M Phase: Mitosis and Cytokinesis

The M phase encompasses both mitosis (nuclear division) and cytokinesis (cytoplasmic division). Mitosis is divided into five stages. In prophase, chromatin condenses into visible chromosomes, the mitotic spindle begins to form from the centrosomes, and the nucleolus disappears. In prometaphase, the nuclear envelope breaks down and spindle microtubules attach to the kinetochores on each sister chromatid. In metaphase, all chromosomes are aligned at the cell equator (metaphase plate), with each sister chromatid attached to spindle microtubules from opposite poles. In anaphase, the cohesin proteins holding sister chromatids together are cleaved by the enzyme separase, and the separated chromatids are pulled to opposite poles by the shortening of kinetochore microtubules. In telophase, the nuclear envelope reforms around each set of chromosomes, the chromosomes decondense, and the nucleolus reappears.

The spindle assembly checkpoint (SAC) operates during prometaphase and metaphase to ensure that all chromosomes are correctly attached to the spindle before anaphase begins. Even a single unattached kinetochore generates a "wait" signal (the mitotic checkpoint complex, MCC) that inhibits the anaphase-promoting complex/cyclosome (APC/C), preventing the degradation of securin and the activation of separase. Only when all kinetochores are properly attached and under tension does the SAC signal cease, allowing APC/C to trigger the simultaneous separation of all sister chromatids. This checkpoint is remarkably sensitive, capable of detecting a single unattached chromosome among 46.

Cell Cycle Checkpoints

The cell cycle contains three major checkpoints that act as quality control mechanisms. The G1/S checkpoint (restriction point) assesses whether the cell has received sufficient growth signals, has adequate nutrients and energy, and has undamaged DNA before committing to replication. The G2/M checkpoint verifies that DNA replication is complete and that any DNA damage has been repaired before entering mitosis. The spindle assembly checkpoint ensures correct chromosome attachment before allowing sister chromatid separation.

The tumor suppressor protein p53, often described as the guardian of the genome, plays a central role in the DNA damage checkpoints. When DNA damage is detected, the kinases ATM and ATR phosphorylate and stabilize p53, which then activates the transcription of p21, a CDK inhibitor that blocks cell cycle progression. This gives the cell time to repair the damage. If the damage is irreparable, p53 can instead activate the transcription of pro-apoptotic genes such as Bax, Puma, and Noxa, directing the cell to undergo programmed cell death rather than risk propagating dangerous mutations. Mutations in p53 are found in approximately 50 percent of all human cancers, making it the most commonly mutated gene in cancer.

Cyclins and Cyclin-Dependent Kinases

The engine that drives the cell cycle forward is a family of protein kinases called cyclin-dependent kinases (CDKs) that are activated by binding to regulatory proteins called cyclins. Different cyclin-CDK combinations operate at different phases of the cycle: cyclin D-CDK4/6 in G1, cyclin E-CDK2 at the G1/S transition, cyclin A-CDK2 during S phase, and cyclin B-CDK1 at the G2/M transition. The sequential activation and destruction of these complexes creates a unidirectional progression through the cycle that cannot be reversed.

Cyclins get their name from their cyclical pattern of accumulation and destruction. Each cyclin is synthesized during a specific phase and then rapidly destroyed by ubiquitin-mediated proteolysis when its function is no longer needed. The APC/C (anaphase-promoting complex/cyclosome) and SCF (Skp1-Cullin-F-box) complexes are E3 ubiquitin ligases that tag specific cyclins for destruction by the proteasome. This destruction is irreversible, which is why the cell cycle moves in only one direction. The entire control system functions as a series of biochemical switches that flip forward but cannot flip back, ensuring orderly progression from one phase to the next.

When the Cell Cycle Goes Wrong

Cancer is fundamentally a disease of cell cycle dysregulation. Mutations that activate oncogenes (such as Ras, Myc, or cyclin D) drive cells to proliferate when they should be quiescent. Mutations that inactivate tumor suppressors (such as p53, Rb, or the CDK inhibitors p21 and p27) remove the brakes that normally restrain proliferation. Most cancers require the accumulation of multiple such mutations, typically 4 to 7, before a cell acquires the full set of capabilities needed for uncontrolled growth, invasion, and metastasis.

Many cancer therapies target the cell cycle directly. Traditional chemotherapy drugs like taxol (paclitaxel) stabilize microtubules and prevent spindle function, trapping dividing cells in mitosis and triggering apoptosis. Newer targeted therapies include CDK4/6 inhibitors (palbociclib, ribociclib) that block the G1/S transition in hormone receptor-positive breast cancer, and checkpoint kinase inhibitors that prevent cancer cells from repairing DNA damage, making them more vulnerable to radiation and DNA-damaging chemotherapy.